# FDA 483 - Cyrus Caroom, M.D. - May 02, 2025

Source: https://www.keypedia.com/records/483/cyrus-caroom-md/42d17248-4a35-40a0-99fd-a376a3ad78b9

> FDA 483 for Cyrus Caroom, M.D. on May 02, 2025. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Cyrus Caroom, M.D.
- Inspection Date: 2025-05-02
- Product Type: drugs
- Office Name: Dallas District Office
- Summary: An FDA inspection of Cyrus Caroom, M.D. in Lubbock, TX, revealed significant deficiencies in the conduct of clinical trials. Observations included failures in obtaining proper informed consent, ensuring adequate IRB review, maintaining complete case histories, and managing investigational drug disposition records. These issues indicate serious non-compliance with regulations governing human subject protection and clinical data integrity.

## Related Officers

- [Joanne M. Schlossin](https://www.keypedia.com/people/joanne-m-schlossin/5cb48b8a-d885-4b4f-8c60-d4714d65603d)

Company: https://www.keypedia.com/companies/cyrus-caroom-md/423ad9ef-e706-41a8-a585-4354119c5ca5

Office: https://www.keypedia.com/offices/dallas-district-office/2d1ee9ae-c44c-4494-8186-a920a69b98f9